Oral Semaglutide's Pharmacokinetic Robustness to Missed Doses Compared to Other GLP-1s Explored in Commentary
Comment on 'The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies'.
Abstract
A recent commentary critically examines the pharmacokinetic profile of oral semaglutide and its resilience to missed doses, contrasting it with other GLP-1-based therapies.